Companies › CereMark Pharma
1 active drug program in 1 registered trial: 1 Phase 3; Neurology; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| [F-18]Flornaptitril Tau imaging agent (positron emission tomography tracer) | – | Phase 3 | Alzheimer Disease | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06254469 | [F-18]Flornaptitril | Phase 3 | Alzheimer Disease | Neurology | Jun 2028 |
No annotated target.
–
Prilenia Ambros Therapeutics Cerevance Green Valley (Shanghai) Pharmaceuticals MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.